• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>St. Jude Medical

St. Jude Medical

St Jude Medical Inc STJ 3 Star

Last Price$63.57Day Change (%)0.46%
Open Price$63.39Day Change ($)0.29
Day Range63.14–63.6752-Week Range51.79–71.90

As of Thu 09/18/2014 01:30 PM EST | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Twelve-Month Data from St . Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

    Twelve-Month Data from St . Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

  2. Large-scale Study Confirms Growing Body of Clinical Evidence for the St . Jude Medical Quadripolar System

    Large-scale Study Confirms Growing Body of Clinical Evidence for the St . Jude Medical Quadripolar System

  3. New Clinical Trial Results Demonstrate Importance of St . Jude Medical Fractional Flow Reserve in Guiding Treatment of NSTEMI Patients

    New Clinical Trial Results Demonstrate Importance of St . Jude Medical Fractional Flow Reserve in Guiding Treatment of NSTEMI Patients

  4. St . Jude Medical to Present at the Morgan Stanley Global Healthcare Conference

    St . Jude Medical to Present at the Morgan Stanley Global Healthcare Conference

  5. Research and Markets: Cardiac Pacemaker Market in India 2014

    Research and Markets: Cardiac Pacemaker Market in India 2014

  6. Research and Markets: Global Heart Defect Closure Devices Market Report 2014-2018 - Boston Scientific, St . Jude Medical & W.L. Gore and Associates Dominates

    Research and Markets: Global Heart Defect Closure Devices Market Report 2014-2018 - Boston Scientific, St . Jude Medical & W.L. Gore and Associates Dominates

  7. GI Dynamics, Inc. Announces the Appointment of Medical Device Industry Veteran Michael D. Dale as President & Chief Executive Officer

    GI Dynamics, Inc. Announces the Appointment of Medical Device Industry VeteranĀ Michael D. Dale as President & Chief Executive Officer

  8. No Surprises in Medtronic's Fiscal Third Quarter

    The firm is on track to meet our full-year estimates, and our $60 per share fair value estimate and wide moat rating are intact.

  9. Our Outlook for the Credit Markets

    Widening investment-grade credit spreads and rising interest rates lead to losses.

  10. Tides Turn for These Orthopedic Firms

    Industry dynamics are shifting in the wake of Zimmer's Biomet acquisition.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.